Pediatrics |

Rate of Hospitalizations Due to Respiratory Events With Tobramycin Inhalation Powder in Patients With Cystic Fibrosis FREE TO VIEW

Stanley Fiel, MD; Samya Nasr, MD; Robert Wan, PhD; Gerhild Angyalosi, MD; Florian Brockhaus, PhD; Robert Maykut, MD; Anthony Yadao, MD
Author and Funding Information

Morristown Medical Center/AtlanticHealth System, Morristown, NJ

Chest. 2013;144(4_MeetingAbstracts):756A. doi:10.1378/chest.1702572
Text Size: A A A
Published online


SESSION TITLE: Hot Topics in Pediatic Pulmonology

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Monday, October 28, 2013 at 01:45 PM - 03:15 PM

PURPOSE: Tobramycin Inhalation Powder (TIP; 112 mg BID) has been shown to improve lung function vs. placebo (EVOLVE) and significantly reduce administration time vs. Tobramycin inhalation solution (TIS; 300 mg BID; EAGER) in patients (pts) with cystic fibrosis (CF) & Pseudomonas aeruginosa (Pa) infection. We report the rate of hospitalizations due to respiratory events from 2-placebo controlled trials (EVOLVE and EDIT) & one comparative trial vs. TIS (EAGER).

METHODS: Two trials were randomized double-blind (28 days-on; 28 days-off) multicenter studies in CF pts (age 6-21) with Pa infection & FEV1 25%-80% predicted receiving TIP (EVOLVE, n=46; EDIT, n=32) or placebo (EVOLVE, n=49; EDIT, n=30). EAGER was a 3-cycle open-label trial of TIP vs. TIS in CF pts ≥6 years & FEV1 25% -75% predicted; randomized 3:2 to TIP (n=308) or TIS (n=209). Hospitalization for respiratory-related events was a secondary or exploratory end point in the 3 studies.

RESULTS: All pts in EVOLVE & EDIT and 30% of EAGER pts were < 22 years. In both placebo-controlled trials, no pts in the TIP arm were hospitalized due to respiratory events during cycle-1, whereas 6 (12.2%) & 1 (3.3%) placebo pts were hospitalized, with mean length of stay of 12.3 and 10 days (d) in EVOLVE & EDIT respectively. In EAGER, hospitalization rates over 3-cycles were similar for TIP & TIS (24.4% vs. 22.0%, treatment difference: 2.3% [-5.2%, 9.6%] p=0.54), with mean duration of 10d & 13d.

CONCLUSIONS: TIP significantly reduced hospitalization rates due to respiratory events compared with placebo. Hospitalization rates were higher in EAGER in both TIP & TIS arms than in EVOLVE & EDIT (possibly due to observation time: 1-cycle for EVOLVE & EDIT vs. 3-cycle for EAGER and likely due to higher % of adults in EAGER); however rates were similar between TIP & TIS.

CLINICAL IMPLICATIONS: In CF patients, TIS and TIP provide similar reductions in rate of hospitalizations due to respiratory events.

DISCLOSURE: Stanley Fiel: Grant monies (from industry related sources): Novartis,CFF, MPEX,Gilead, Vertex, Consultant fee, speaker bureau, advisory committee, etc.: Consultant at Novartis, Bayer, Pfizer, Boehringer Ingelheim, Consultant fee, speaker bureau, advisory committee, etc.: speakers bureau- Pfizer, Genetech, Novartis, Gilead, GSK, Dey Samya Nasr: Consultant fee, speaker bureau, advisory committee, etc.: Consultant Novartis, Consultant fee, speaker bureau, advisory committee, etc.: Speaker bureau-Gilead, Novartis, Consultant fee, speaker bureau, advisory committee, etc.: Advisory Committee-Gilead, Genentech, Grant monies (from industry related sources): Researcher-Vertex, Gilead, Mpex, Hologic, , Grant monies (from sources other than industry): Researcher-CFF Robert Wan: Employee: Novartis Pharmaceuticals Corporation Gerhild Angyalosi: Employee: Novartis Pharma AG Florian Brockhaus: Employee: Novartis Pharma AG Robert Maykut: Employee: Novartis Pharma AG Anthony Yadao: Employee: Novartis Pharmaceuticals Corporation

Tobramycin Inhalation Powder (TOBI® Podhaler)was approved by US FDA on 22 March 2013.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543